{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:49:02Z","timestamp":1764859742460,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["FAT-BC 101003153"],"award-info":[{"award-number":["FAT-BC 101003153"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015230","name":"Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013845","name":"Fondation contre le Cancer","doi-asserted-by":"publisher","award":["FAF- C\/2018\/1302"],"award-info":[{"award-number":["FAF- C\/2018\/1302"]}],"id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011928","name":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030958","name":"ETOP IBCSG Partners Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115438","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:32:20Z","timestamp":1744878740000},"page":"115438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial"],"prefix":"10.1016","volume":"222","author":[{"given":"Giacomo","family":"Biganzoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Isnaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4353-3619","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-7297","authenticated-orcid":false,"given":"Giuseppe","family":"Marano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-2005","authenticated-orcid":false,"given":"Patrizia","family":"Boracchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Maetens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-5425","authenticated-orcid":false,"given":"Giuseppe","family":"Floris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-0043","authenticated-orcid":false,"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-3878","authenticated-orcid":false,"given":"Elisabetta","family":"Munzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Hitre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-2369","authenticated-orcid":false,"given":"Andrea","family":"Gombos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-9449","authenticated-orcid":false,"given":"Stefan","family":"Aebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-7894","authenticated-orcid":false,"given":"Roswitha","family":"Kammler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-0829","authenticated-orcid":false,"given":"Patrizia","family":"Dell\u2019Orto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1882-7068","authenticated-orcid":false,"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith M.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5743-3013","authenticated-orcid":false,"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5223-5579","authenticated-orcid":false,"given":"Christine","family":"Desmedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ejca.2025.115438_bib1","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115438_bib2","unstructured":"Mcpherson K., Brown M., Brown Associates M. Foresight Tackling Obesities: Future Choices-Modelling Future Trends in Obesity and the Impact on Health 2 nd Edition. [cited 2022 Aug 1]; Available from: \u3008www.foresight.gov.uk\u3009."},{"key":"10.1016\/j.ejca.2025.115438_bib3","series-title":"Adiposity and cancer risk: New mechanistic insights from epidemiology [Internet], Nature Reviews Cancer, Vol. 15","first-page":"484","author":"Renehan","year":"2015"},{"key":"10.1016\/j.ejca.2025.115438_bib4","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","article-title":"Obesity and breast cancer prognosis: Evidence, challenges, and opportunities [Internet]","author":"Jiralerspong","year":"2016","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115438_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab023","article-title":"Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis","author":"Lohmann","year":"2021","journal-title":"JNCI: J Natl Cancer Inst [Internet]"},{"issue":"10","key":"10.1016\/j.ejca.2025.115438_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37780","article-title":"Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors","volume":"6","author":"Harborg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10461","key":"10.1016\/j.ejca.2025.115438_bib7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(24)01745-8","article-title":"Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155\u2008746 women in 151 trials","volume":"404","author":"Breast Cancer Trialists","year":"2024","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.ejca.2025.115438_bib8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115438_bib9","article-title":"Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) database","author":"Hongchao","year":"2024","journal-title":"Abstr GS2-09 [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","article-title":"Effect of obesity on prognosis after early-stage breast cancer","volume":"29","author":"Ewertz","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115438_bib11","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/ijc.29940","article-title":"A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis","volume":"138","author":"Nechuta","year":"2016","journal-title":"Int J Cancer [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jnci\/djx134","article-title":"Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05)","volume":"110","author":"Blok","year":"2018","journal-title":"JNCI: J Natl Cancer Inst [Internet]"},{"key":"10.1016\/j.ejca.2025.115438_bib13","unstructured":"Gnant M. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. 2021."},{"issue":"10","key":"10.1016\/j.ejca.2025.115438_bib14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.annonc.2021.07.017","article-title":"Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy","volume":"32","author":"Jerusalem","year":"2021","journal-title":"Ann Oncol [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(17)30715-5","article-title":"Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Colleoni","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115438_bib16","unstructured":"A healthy lifestyle - WHO recommendations [Internet]. [cited 2022 Aug 1]. Available from: \u3008https:\/\/www.who.int\/europe\/news-room\/fact-sheets\/item\/a-healthy-lifestyle---who-recommendations\u3009."},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","article-title":"Effect of obesity on prognosis after early-stage breast cancer","volume":"29","author":"Ewertz","year":"2010","journal-title":"J Clin Oncol [Internet]"},{"issue":"11","key":"10.1016\/j.ejca.2025.115438_bib18","first-page":"2389","article-title":"Tutorial in biostatistics","volume":"26","author":"Putter","year":"2007","journal-title":"Compet risk multi-State Models Stat Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib19","first-page":"1","article-title":"Model-based estimation of measures of association for time-to-event outcomes","volume":"14","author":"Ambrogi","year":"2014","journal-title":"BMC Med Res Method [Internet]"},{"key":"10.1016\/j.ejca.2025.115438_bib20","article-title":"Regression modeling strategies","author":"Harrell","year":"2017","journal-title":"Bios"},{"year":"2020","series-title":"R: A language and environment for statistical computing","author":"R Core Team [Internet]","key":"10.1016\/j.ejca.2025.115438_bib21"},{"key":"10.1016\/j.ejca.2025.115438_bib22","article-title":"The R package geepack for generalized estimating equations [Internet]","volume":"15","author":"Halekoh","year":"2006","journal-title":"JSS J Stat Softw"},{"key":"10.1016\/j.ejca.2025.115438_bib23","unstructured":"Bretz F., Westfall P., Hothorn T. 2008. Simultaneous Inference in General Parametric Models. [cited 2023 Mar 28]; Available from: http:\/\/www.stat.uni-muenchen.de."},{"issue":"14","key":"10.1016\/j.ejca.2025.115438_bib24","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2000.18.14.2702","article-title":"Time-dependent relevance of steroid receptors in breast cancer","volume":"18","author":"Coradini","year":"2000","journal-title":"J Clin Oncol [Internet]"},{"issue":"3","key":"10.1016\/j.ejca.2025.115438_bib25","doi-asserted-by":"crossref","DOI":"10.3109\/09513590.2012.736559","article-title":"Body mass index (BMI) and breast cancer: impact on tumor histopatologic features, cancer subtypes and recurrence rate in pre and postmenopausal women","volume":"29","author":"Biglia","year":"2013","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib26","article-title":"Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics","volume":"5","author":"Blair","year":"2019","journal-title":"NPJ Breast Cancer [Internet]"},{"issue":"2","key":"10.1016\/j.ejca.2025.115438_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10147-014-0712-4","article-title":"Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index","volume":"20","author":"Santa-Maria","year":"2015","journal-title":"Int J Clin Oncol [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib28","article-title":"Relationship of breast volume, obesity and central obesity with different prognostic factors of breast cancer","volume":"11","author":"Lubi\u00e1n L\u00f3pez","year":"2021","journal-title":"Sci Rep [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-022-06836-5","article-title":"A retrospective study in tumour characteristics and clinical outcomes of overweight and obese women with breast cancer","volume":"198","author":"Lu\u00eds","year":"2023","journal-title":"Breast Cancer Res Treat [Internet]"},{"issue":"12","key":"10.1016\/j.ejca.2025.115438_bib30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/nm1202-1341","article-title":"Breast cancer: aromatase inhibitors take on tamoxifen","volume":"8","author":"Dowsett","year":"2002","journal-title":"Nat Med [Internet]"},{"issue":"3","key":"10.1016\/j.ejca.2025.115438_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1677\/joe.0.0990455","article-title":"Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens","volume":"99","author":"Wakeling","year":"1983","journal-title":"J Endocrinol [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol [Internet]"},{"issue":"4","key":"10.1016\/j.ejca.2025.115438_bib33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1200\/JCO.2002.20.4.1026","article-title":"Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer","volume":"20","author":"Harper-Wynne","year":"2002","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.ejca.2025.115438_bib34","unstructured":"Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen - PubMed [Internet]. [cited 2024 Jul 31]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/3123050\/\u3009."},{"issue":"10","key":"10.1016\/j.ejca.2025.115438_bib35","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.2007.13.9279","article-title":"Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer","volume":"26","author":"Dixon","year":"2008","journal-title":"J Clin Oncol [Internet]"},{"issue":"15_","key":"10.1016\/j.ejca.2025.115438_bib36","article-title":"Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial","volume":"28","author":"Pfeiler","year":"2010","journal-title":"J Clin Oncol [Internet]"},{"issue":"3","key":"10.1016\/j.ejca.2025.115438_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10549-010-1153-z","article-title":"Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association","volume":"126","author":"Majed","year":"2011","journal-title":"Breast Cancer Res Treat [Internet]"},{"key":"10.1016\/j.ejca.2025.115438_bib38","first-page":"1901","article-title":"Body mass index and survival in women with breast cancer\u2014systematic literature review and meta-analysis of 82 follow-up studies [Internet]","volume":"25","author":"Chan","year":"2014"},{"issue":"33","key":"10.1016\/j.ejca.2025.115438_bib39","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1200\/JCO.23.00126","article-title":"Impact of BMI in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS Trial","volume":"41","author":"Pfeiler","year":"2023","journal-title":"J Clin Oncol [Internet]"},{"issue":"1","key":"10.1016\/j.ejca.2025.115438_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.ejca.2025.115438_bib41","first-page":"15","article-title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib +\u2009endocrine therapy versus endocrine therapy alone in patients with HR+\u2009\/HER2\u2212 early breast cancer","author":"Slamon","year":"2023","journal-title":"Ther Adv Med Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:36:04Z","timestamp":1762342564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"alternative-id":["S0959804925002199"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115438","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115438"}}